BIOLIGHT LIFE SCIENCES LTD. BioLight Life Sciences Ltd. Share Price
Equities
BOLT
IL0010952237
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 352.2 ILa | +0.03% |
|
+4.08% | -32.23% |
| Sales 2022 | 63K 16.83K 6.3M 1.4M | Sales 2023 | 118K 31.51K 11.8M 2.63M | Capitalization | 24.12M 6.44M 2.41B 537M |
|---|---|---|---|---|---|
| Net income 2022 | -7M -1.87M -700M -156M | Net income 2023 | -26M -6.94M -2.6B -579M | EV / Sales 2022 | 207 x |
| Net cash position 2022 | 17.1M 4.57M 1.71B 381M | Net cash position 2023 | 8.55M 2.28M 855M 191M | EV / Sales 2023 | 132 x |
| P/E ratio 2022 |
-3.85
x | P/E ratio 2023 |
-0.93
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.16% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.03% | ||
| 1 week | +4.08% | ||
| Current month | -17.83% | ||
| 1 month | -17.83% | ||
| 3 months | -32.81% | ||
| 6 months | -35.96% | ||
| Current year | -32.23% |
1 week
338.30
363.00
1 month
334.30428.60
Current year
334.30564.90
1 year
334.30720.00
3 years
334.301 364.00
5 years
334.301 420.00
10 years
334.305 100.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 01/20/01 | |
Yifftach Biel
DFI | Director of Finance/CFO | 48 | 01/15/01 |
Ron Neumann
CTO | Chief Tech/Sci/R&D Officer | 69 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Israel Makov
CHM | Chairman | 85 | 21/11/21 |
Kobi Faigenbaum
BRD | Director/Board Member | 71 | 11/17/11 |
Alla Felder
BRD | Director/Board Member | 50 | 25/20/25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 352.2 | +0.03% | 7 664 |
| 01/24/01 | 352.1 | +2.50% | 154,099 |
| 30/24/30 | 343.5 | +1.51% | 3,509 |
| 25/24/25 | 338.4 | 0.00% | 200 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 02, 2024 at 12:53 pm IST
More quotes
Biolight Life Sciences Ltd, formerly Bio Light Israeli Life Sciences Investments Ltd, is an Israel-based company engaged, through its subsidiaries, in various fields of research and development of pharmaceuticals and medical products and devices. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The Company provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.
| 1st Jan change | Capi. | |
|---|---|---|
| -32.23% | 4.37M | |
| +8.33% | 219B | |
| +6.72% | 183B | |
| +10.18% | 132B | |
| +24.91% | 106B | |
| -2.09% | 62.09B | |
| +10.56% | 50.8B | |
| +4.81% | 50.88B | |
| -0.24% | 40.64B | |
| +1.22% | 35.71B |
- Stock Market
- Equities
- BOLT Stock
